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Abstract
Background: Trismus occurs frequently in patients with head and neck cancer.
Determining the prevalence and associated factors of trismus would enable predic-
tion of the risk of trismus for future patients.
Methods: Based on maximal mouth opening measurements, we determined the
prevalence of trismus in 730 patients with head and neck cancer. Associated factors
for trismus were analyzed using univariate analyses and multivariate logistic
regression analyses. Based on the regression model, a calculation tool to predict
trismus was made.
Results: Prevalence of trismus was 23.6%. Factors associated with trismus were:
advanced age; partial or full dentition; tumors located at the maxilla; mandible;
cheek; major salivary glands; oropharynx; an unknown primary; a free soft tissue
transfer after surgery; reirradiation; and chemotherapy.
Conclusion: About one-fourth of patients with head and neck cancer develop tris-
mus. Based on prevalence and associated factors of trismus, a simple calculation
tool predicts the risk of trismus in these patients.
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1 | INTRODUCTION
Trismus, also referred to as a restricted mouth opening, is
a common problem in patients with head and neck can-
cer.1 Patients with trismus often experience difficulties in
performing activities of daily living, such as eating, drink-
ing, laughing, and kissing.2–5 These difficulties adversely
affect their quality of life.2–7 Moreover, as the access to
the oral cavity is restricted, intubation, dental treatment,
and oncologic follow-up may become more
complicated.2,6,7
A wide variety in prevalence of trismus (ranging from
5% to 65%) and factors associated with trismus have been
found due to narrow inclusion criteria, a single tumor
localization,5,8,9 one treatment modality,4,5,8–11 small sample
sizes,8,9 and different cutoff points for trismus.8,11,12
Due to this wide variety and lack of clarity about the
prevalence of trismus and the associated factors, clinicians
are uncertain about when to take precautionary measures to
prevent trismus. If patients at risk for trismus could be iden-
tified early, they could potentially benefit from preventive
measures. In this study, based on a large study population
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(n = 730) with a variety of tumor and treatment characteris-
tics, we, therefore, determined the prevalence of trismus and
identified associated factors for trismus in patients with head
and neck cancer.
2 | MATERIALS AND METHODS
2.1 | Patients
In this cross-sectional study, patients with head and neck
cancer were included who visited the Department of Oral
and Maxillofacial Surgery of the University Medical Center
Groningen (Netherlands) between November 2012 and
January 2015. Their maximal mouth opening was measured
as part of routine care. Patients were included if they had a
tumor located in the upper aerodigestive tract, unknown pri-
maries with metastases in the head and neck region, or a
major salivary gland tumor. Patients were excluded if they
visited the Oral and Maxillofacial Surgery Department for a
consultation but were not diagnosed with head and neck can-
cer or had a rare type of tumor, were younger than 18 years,
or had missing data regarding maximal mouth opening
(MMO) measurements. Our study was carried out according
to the regulations of our institute. The Medical Ethical Com-
mittee of the University Medical Center Groningen con-
cluded that our research was not subject to the Medical
Research (Human Subject) Act (METc number 2016.692).
2.2 | Maximal mouth opening measurement and
dental status
The MMO was measured and recorded on a registration
form by one of the oral and maxillofacial surgeons, nurse
practitioners, or residents, using the OraStretch Range-of-
Motion Scale (Craniomandibular Rehab, Denver, CO) dur-
ing a visit at the department of Oral and Maxillofacial Sur-
gery. This visit could have taken place before or after head
and neck cancer treatment. The OraStretch Range-of-Motion
Scale is a disposable paper measurement tool, which mea-
sures MMO in millimeters (mm), with a scale range from
3 to 52 mm. Because OraStretch Range-of-Motion Scale is
limited to 52 mm, patients with a MMO of 52 mm or more
were measured using a sliding caliper (in mm).
Additionally, the dental status was recorded. Patients
were recorded as “dentate” in cases in which they had frontal
dentition or wore prosthesis.
The incisal edge of the right upper central incisor and the
right lower central incisor was used as the measurement
points. Patients were recorded as “edentulous” if they had no
frontal dentition and wore no prosthesis.
The top of the alveolar ridge at the former location of the
right upper and lower central incisor were used as measure-
ment points. Patients were recorded as “partially edentulous”
if they had a frontal dentition or wore prosthesis in one jaw
(upper or lower jaw) and had no dentition or wore no pros-
thesis on the other jaw (upper or lower jaw).
2.3 | Data
The following data were recorded on the registration form:
patient identification number; date of birth; sex; dental status
(dentate, partially edentulous, and edentulous); MMO mea-
surement (in mm); and date of measurement. Additional data
were retrieved from the patient file in the hospital information
system: cT classification based on the Union for International
Cancer Control TNM classification 2009 (TX, T1-2, T3-4, and
unknown); tumor localization (tongue, floor of mouth, maxilla,
mandible, cheek, major salivary glands, oropharynx, hypo-
pharynx and larynx, lip, unknown primary, and others); squa-
mous cell carcinoma (yes or no); surgery (no surgery, surgery,
or multiple surgical procedures); neck dissection (yes or no);
reconstruction after surgery (no reconstruction, skin graft, soft
tissue flap, plates, or bony tissue flap); radiotherapy
(no radiotherapy, radiotherapy, or reirradiation); chemotherapy
(yes or no); and trismus treatment (yes or no).
To classify the extension of the primary tumor, the cT
classification was used instead of the pT classification
because the cT classification had least missing data. Not
every tumor was treated surgically, so pathologic staging
was often not available.
No reconstruction was recorded in case of primary wound
closure or in case no surgery was performed. A soft tissue flap
was recorded in case of a pectoralis major flap, nasolabial flap,
or radial forearm flap. A bony tissue flap was recorded in case
of a fibula osteocutaneous flap. Because the soft tissue flaps
involve different procedures and are harvested from different
locations we have chosen to combine these flaps in the univar-
iate and multivariate analyses in order to enable sufficient
numbers in each group for analyses and preserve as much data
as possible. Specified information about the soft tissue flaps
are displayed in the descriptive table (Table 1).
2.4 | Statistics
Prevalence of trismus was calculated using the cutoff point
of an MMO of 35 mm or less. The chi-square test and t test
for independent samples were used to analyze the differ-
ences between patients with and without trismus in age, sex,
dental status, cT classification, tumor localization, surgery,
reconstruction after surgery, radiotherapy, and chemother-
apy. Based on statistical significance (P < .10), variables
were entered in the multivariable logistic regression ana-
lyses. A P value of .10 was chosen in order to prevent miss-
ing potential associated factors. Thereafter, variables with a
P value of > .05 were removed stepwise. If the model fit
improved significantly (based on the Omnibus Tests of
Model Coefficients), the variables remained in the model.
Interaction effects were explored as well. In the final model,
the variable “age” was standardized to improve clinical
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interpretation; the individual age was subtracted from the
mean age of the study population. The validity of our final
model was tested based on the assessment of discrimination
(using the area under the curve) and calibration (using the
Hosmer-Lemeshow test).
A risk score for trismus was calculated as the sum of the
regression coefficients of our final logistic regression model.
The reference categories were given a value of zero for their
regression coefficients.
For the variable “standardized age,” the mean age was
subtracted from the age of the patient. The standardized age
was multiplied by the regression coefficient for the variable
“standardized age.” For the interaction effect “standardized
age*radiotherapy,” the standardized age is multiplied by the
corresponding regression coefficient. The regression coeffi-
cient of the “constant” was always added to the calculation.
We calculated a range of probabilities (P) based on the for-
mula “ln (P/1-P) = risk score for trismus.” Using the calcu-
lated risk score for trismus, the risk for trismus for future
patients can be estimated.
Our study population consisted of all included patients
who had head and neck cancer. Of this study population,
some patients had multiple tumors receiving multiple treat-
ments. To verify the final logistic regression model, we also
studied a population that only had one primary tumor.
Analyses were performed using IBM SPSS Statistics
Program version 23.0 (IBM, Armonk, NY).
3 | RESULTS
3.1 | Study population
The MMO of 839 patients was recorded during visits at the
department of Oral and Maxillofacial Surgery. In total,
109 patients were excluded because 78 patients were not
diagnosed with head and neck cancer; 29 patients had rare
types of tumors, and 2 patients had missing data regarding
MMO measurement. Of the 138 patients who had an MMO
of 52 mm or larger, 112 patients were measured with a slid-
ing caliper and 26 patients were recorded as having an
MMO of 52 mm, because a sliding caliper was unavailable
at that time. Ultimately, the total study population consisted
of 730 patients (87.0%; Table 1).
The results of the total study population are reported.
The results of the study population with only primary tumors
are reported in the Supporting Information Tables S1-S3.
The univariate analysis of the study population with
only primary tumors differs from the univariate analysis of
the total study population, as the variables dental status
and surgery are not significantly associated with trismus
(Table 2 and Supporting Information Table S2). However,
for the multivariate logistic regressions model, the same
variables are inserted into the model to analyze which vari-
ables contribute significantly to the equation. The multi-
variate logistic regression model of the study population
with only primary tumors shows that dental status contrib-
utes significantly to the equation. The interaction
TABLE 1 Patient, tumor, and treatment characteristics of total study
population (n = 730)
Characteristics No. of patients (%)
Male 388 (53.2)
Deceased 63 (8.6)
Age, years, mean (SD) 63.6 (13.5)
Dental status
Fully dentulous 575 (79.4)
Fully edentulous 104 (14.4)
Partially edentulous 45 (6.2)
cT classification
T1, T2 450 (74.4)
T3, T4 155 (25.6)
Tongue 164 (25.4)




Major salivary glands 73 (11.3)
Oropharynx 111 (17.2)
Lip 54 (8.4)
Unknown primary 12 (1.9)
Hypopharynx and larynx 32 (5.0)
Squamous cell carcinoma 510 (69.9)
Surgery
Surgery 444 (60.8)
Multiple surgical procedures 62 (8.5)
Neck dissection
Neck dissection 251 (34.4)
Multiple neck dissections 25 (3.4)
Reconstruction after surgery
Skin graft 118 (16.2)
Soft tissue flap 31 (4.2)
Radial forearm flap 28 (3.8)
Nasolabial flap 2 (0.3)
Pectoralis major flap 1 (0.1)
Plates 11 (1.5)
Solitary plate 4 (0.5)
Radial forearm flap and plate 2 (0.3)
Nasolabial flap and plate 1 (0.1)
Pectoralis major flap and plate 4 (0.5)





Exercise therapy 47 (6.5)
Missing values (no. of patients; %): dental status (6; 0.8), cT classification
(125; 17.1), tumor localization (84; 11.5), squamous cell carcinoma (84;
11.5), neck dissection (1; 0.1), and reconstruction (32; 4.4).
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“standardized age*radiotherapy” did not contribute signifi-
cantly to the equation (Table 3 and Supporting Information
Table S3).
3.2 | Prevalence
In our study, 23.6% of the patients had trismus (n = 172).
Compared to patients without trismus, patients with trismus
were older, were partially edentulous or dentate more fre-
quently, had advanced tumors (T3 or T4) more frequently,
had tumors located near the maxilla, mandible, cheek,
oropharynx, or had an unknown primary more frequently,
underwent multiple surgical procedures, neck dissections,
and/or reconstruction after surgery more frequently, and
received radiotherapy, reirradiation, or chemotherapy more
frequently (Table 2).
3.3 | Selecting potential factors
In the univariate analysis, the following variables were sig-
nificantly associated with trismus: age (P = .011), dental sta-
tus (P = .036), tumor size (P < .001), tumor localization
TABLE 2 Comparison between patients with and without trismus
No. of patients without trismus (n = 558) No. of patients with trismus (n = 172)
No. % No. % Chi-square DF P value
Male sex 304 54.5 84 48.8 1.681 1 .195
Dental status 6.650 2 .036
Dentate 437 79.0 138 80.7
Partially edentulous 29 5.2 16 9.4
Edentulous 87 15.7 17 9.9
cT classification 23.059 2 < .001
T1, T2 360 79.3 90 59.6
T3, T4 94 20.7 61 40.4
Tumor localization 42.683 9 < .001
Tongue 134 27.6 30 18.6
Floor of mouth 76 15.7 16 9.9
Maxilla 21 4.3 15 9.3
Mandible 30 6.2 21 13.0
Cheek 10 2.1 11 6.8
Major salivary glands 55 11.3 18 11.2
Oropharynx 74 15.3 37 23.0
Lip 50 10 4 2.5
Unknown primary 8 1.6 4 2.5
Hypopharynx and larynx 27 5.6 5 3.1
Surgery
Surgery 348 62.4 96 55.8 10.677 2 .005
Multiple surgical procedures 37 6.6 25 14.5
Neck dissection
Neck dissection 173 31.1 78 45.3 15.791 2 < .001
Multiple neck dissections 16 2.9 9 5.2
Reconstruction after surgery 25.083 4 < .001
Skin graft 85 16.0 33 19.8
Soft tissue flap 16 3.0 15 9.0
Plates 7 1.3 4 2.4
Bony tissue flap 27 5.1 19 11.4
No reconstruction 396 74.6 96 57.5
Radiotherapy
Radiotherapy 163 29.2 73 42.4 13.926 2 .001
Reirradiation 14 2.5 8 4.7
Chemotherapy 59 10.6 36 20.9 12.458 1 < .001
Mean SD Mean SD DM 95% CI P value
Age, years 62.9 13.6 65.9 12.9 -3.0 -5.3; -0.7 .011a
Abbreviations: CI, confidence interval; DF, degrees of freedom; DM, difference in means.
a The t test was used for independent samples.
VAN DER GEER ET AL. 67
(P < .001), surgery (P = .005), neck dissection (P < .001),
reconstruction after surgery (P < .001), radiotherapy (P =
.001), and chemotherapy (P < .001; Table 2). These poten-
tial factors were entered in the logistic regression model.
3.4 | Logistic regression analyses
Our final regression model (Nagelkerke's R2 0.233, percent-
age correctly predicted 78.1%) contained the variables:
standardized age, dental status, tumor localization, recon-
struction after surgery, radiotherapy, chemotherapy, and
interaction effect “standardized age*radiotherapy” (Table 3).
Other interaction effects among standardized age, dental sta-
tus, tumor localization, reconstruction after surgery,
radiotherapy, and chemotherapy were explored as well but
did not contribute significantly to the regression equation.
The area under the curve was 0.764 (95% confidence
interval [CI] 0.720-0.807; P < .001), indicating that the
model classifies the groups significantly better than by
chance. The Hosmer and Lemeshow test was not significant
(P = .865), indicating that there was no disagreement
between the predicted and observed values.
3.5 | Risk score trismus
Based on our model, the risk score for trismus for a hypo-
thetical patient can be calculated as follows using arbitrarily
chosen characteristics. A patient is 68 years old, is partially
edentulous, and has a tumor located near the oropharynx.
TABLE 3 Results of multivariate logistic regression analysis to identify the contribution of associated factors of trismus
95% CI
β OR Lower Upper P value
Age, yearsa 0.030 1.031 1.006 1.055 .013
Dental status .002
Dentate 1.186 3.274 1.679 6.382 .000
Partially edentulous 1.254 3.504 1.346 9.123 .010
Edentulous, RC† 0.000 1.000
Tumor localization .000
Tongue 0.702 2.018 0.680 5.985 .206
Floor of mouth 0.286 1.331 0.405 4.374 .637
Maxilla 1.736 5.673 1.610 19.991 .007
Mandible 1.586 4.883 1.407 16.941 .012
Cheek 2.062 7.858 1.854 33.299 .005
Major salivary glands 1.166 3.208 0.994 10.355 .051
Oropharynx 1.154 3.171 1.079 9.323 .036
Lip -0.311 0.733 0.171 3.138 .675
Unknown primary 1.685 5.392 1.054 27.577 .043
Hypopharynx and larynx, RCb 0.000 1.000
Reconstruction after surgery .010
Skin graft 0.492 1.636 0.921 2.908 .093
Soft tissue flap 1.403 4.067 1.739 9.511 .001
Plates 0.596 1.816 0.411 8.017 .431
Bony tissue flap 0.844 2.326 1.036 5.223 .041
No reconstruction, RCb 0.000 1.000
Radiotherapy .000
Radiotherapy 0.974 2.648 1.622 4.324 .000
Reirradiation 1.756 5.789 1.757 19.070 .004
No radiotherapy, RCb 0.000 1.000
Chemotherapy 1.418 4.129 2.210 7.715 .000
Agea × radiotherapyc .039
Agea × radiotherapyc -0.001 0.999 0.966 1.034 .968
Agea × reirradiationc -0.137 0.872 0.784 0.970 .011
Constant -3.999 0.018 .000
Abbreviations: CI, confidence interval; OR, odds ratio; RC, reference category.
a Age is standardized; the mean age of 63.6 years will be subtracted from the individual age.
b Reference category (variable): edentulous (dental status); hypopharynx and larynx (tumor localization); no reconstruction (reconstruction); no radiotherapy
(radiotherapy).
c Interaction effect of standardized age and radiotherapy.
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The patient will receive radiotherapy. To calculate this
patients' risk score, the regression coefficients of our final
regression model are filled in for this patient (Table 3):
(68-63.6 years; age - mean age) * 0.030 + 1.254 (partially
edentulous) + 1.154 (tumor localization oropharynx) +
0.000 (no reconstruction) + 0.974 (radiotherapy) + 0.000
(no chemotherapy) + (68-63.6) * −0.001 ((age – mean
age)*radiotherapy)) - 3.999 (constant) = −0.489.
In Table 4, it is shown that that the calculated risk score
(regression coefficient sum score) of −0.489 lies between
−0.405 and −0.847. This means that the hypothetical patient
has a risk of developing trismus between 31% and 40%.
4 | DISCUSSION
In our study population of patients with head and neck can-
cer, the prevalence of trismus is 23.6%. We identified the
following characteristics as associated factors for trismus:
older patient age, dentate or partially edentulous dentition,
tumors located near the maxilla, mandible, cheek, major sali-
vary glands, oropharynx, or an unknown primary, a free soft
tissue transfer after surgery, reirradiation, and chemotherapy.
In comparison to the prevalence found in this study,
higher prevalence was reported in study populations that
received radiotherapy predominantly or solely (range 35%-
41%).11,13,14 A lower prevalence (8%) was reported in a
study population including patients treated with surgery
solely. A similar prevalence (28.3%) was reported in patients
who received surgery, radiotherapy, or chemotherapy.12 The
higher prevalence of trismus among patients who received
radiotherapy with or without chemotherapy, compared with
patients who had surgery, is generally the result of a larger
and more extensive field of fibrosis due to prolonged inflam-
matory responses, angiogenesis, and extended and increased
expression of extracellular matrix components.15–17
The differences in prevalence are not only related to
study populations with different treatment characteristics but
also to different patient and tumor characteristics.
Our found association between age and trismus could
not be confirmed by other studies.2,4,13 This could be
explained by the difference in mean age of the study popula-
tion. The mean age in our study population (66.0; SD 12.8
in trismus group and 62.9; SD 13.9 in no trismus group) was
higher than the mean age in another study population (56.4;
SD 7.5 in trismus group and 54.4; SD 13.1 in no trismus
group).4 As the patient gets older, the range of motion
diminishes due to the micro and macro changes of joints and
ligaments, which might also involve the temporomandibular
joint.18
Patients also become frailer as they age, resulting in
increased vulnerability, decreased adaptive capacity, and
longer recovery periods after treatment, enhancing the risk
of trismus even further.19,20 Compared with other studies,
we have a large dataset, therefore, we were able to detect
small effects. As the risk of trismus only increases with
0.030 per year, the enhanced risk per year contributed by
age is small but present. Additionally, a small interaction
effect between age and radiotherapy has been found. We
cannot explain this effect in a plausible biological way. Clin-
ically, this interaction effect suggests that clinicians should
not be too reluctant to choose for reirradiation as cancer
treatment on the basis of the patients' older age.
Tumor size could have an effect on the development of
trismus. However, in contrast with other studies,13,21 we
could not find an association between tumor size, based on
the cT classification, and trismus in our study. Nonetheless,
it seems that a greater extension of the tumor increases the
risk of trismus. We found that dental status and type of
reconstruction were associated with trismus, which could
have been an indirect effect of tumor size. Large tumors
most likely lead to large resections, commonly involving
partial jaw removal, and, therefore, resulting in patients
becoming partially edentulous. Large tumors might also lead
to large reconstructions, leading to a greater field of fibrosis.
One study reported that of 15 patients who had developed
trismus, 14 patients had received a free flap reconstruction,
suggesting that receiving a reconstruction might increase the
risk of trismus.9 However, 13 of the 15 patients received
radiotherapy as well. Therefore, no direct association
between reconstructions and the development of trismus
could be made on the basis of that study.
Due to different tumor localization categorization, no
definite tumor localization can be appointed that increases
the risk of developing trismus. A variety of localizations,
such as the oropharynx, nasopharynx, maxilla, mandible,
maxillary sinus, pterygoid muscles, and masseter muscle, are
mentioned to increase the risk of developing tris-
mus.3,10,13,22,23 In general, it can be stated that tumors
located near the temporomandibular joint and masticatory
muscles will most likely increase the risk of developing tris-
mus. In our study, this statement is confirmed as the maxilla,
mandible, cheek, major salivary glands, and oropharynx are
TABLE 4 Clinical calculation tool to predict trismus
Risk score Probability
Risk score ≤ -2.197 ≤ 0.10
-2.197 < Risk score ≤ -1.386 0.11−0.20
-1.386 < Risk score ≤ -0.847 0.21−0.30
-0.847 < Risk score ≤ -0.405 0.31−0.40
-0.405 < Risk score ≤ 0.000 0.41−0.50
0.000 < Risk score ≤ 0.405 0.51−0.60
0.405 < Risk score ≤ 0.847 0.61−0.70
0.847 < Risk score ≤ 0.386 0.71−0.80
1.386 < Risk score ≤ 2.197 0.81−0.90
> 2.197 > 0.9
This clinical tool can be used to predict the risk of trismus for individual patients.
The risk score calculation is the sum of the regression coefficients from the logis-
tic regression model of Table 3.
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near the temporomandibular joint and the masticatory
muscles.
Tumor infiltration and/or fibrosis near these structures
make it difficult to open the mouth adequately and may also
lead to trismus.22–24
Our large study population consisted of patients with a
variety of tumor and treatment characteristics. Therefore, our
findings can be generalized to patients with head and neck
cancer with different patient, tumor, and treatment character-
istics. However, all patients included in this study were
recruited at the department of Oral and Maxillofacial Sur-
gery, resulting in a predominance of patients with tumors
who were treated with surgery as part of their treatment strat-
egy. As the risk of trismus might be higher among patients
treated with radiotherapy in comparison to surgery, the
recruitment might have resulted into an underestimation of
prevalence of trismus compared to the total head and neck
cancer population.
Another possible limitation of our study is that MMO
was measured by different assessors, which could have
introduced a measurement error. However, a previous study
reported that measurement differences between assessors are
minimal.25
We were not able to measure all patients with an MMO
of 52 mm or more, because the sliding caliper was unavail-
able. Therefore, 26 patients were recorded to have an MMO
of 52 mm. This might have led to some inaccuracy in our
database. However, it was certain that these patients did not
have a trismus. As we have dichotomized trismus, this inac-
curacy has minor influence on our results.
In this study, we developed a simple calculation tool to
predict the risk of trismus for future patients. No complex
calculations are needed. The tool should be seen as a guide-
line or relative prediction tool when used in other popula-
tions. No absolute risk scores for other populations can be
made on the basis of this tool.
The recognition of factors associated with trismus and
the simple calculation tool will enable clinicians to take pre-
cautionary measures as soon as possible, if needed.26–28 In
future studies, the associated factors for trismus can be taken
into account when recruiting patients to study the effective-
ness of preventive exercise trismus therapy.
5 | CONCLUSION
About one-fourth of patients with head and neck cancer
develop trismus. We provide a simple calculation tool to pre-
dict the risk of trismus in patients with head and neck
cancer.
CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest
with the contents of this article.
ORCID
Sarah J. van der Geer https://orcid.org/0000-0002-5766-054X
REFERENCES
1. Kamstra JI, Jager-Wittenaar H, Dijkstra PU, et al. Oral symptoms and func-
tional outcome related to oral and oropharyngeal cancer. Support Care Can-
cer. 2011;19:1327-1333.
2. Scott B, Butterworth C, Lowe D, Rogers SN. Factors associated with
restricted mouth opening and its relationship to health-related quality of life
in patients attending a maxillofacial oncology clinic. Oral Oncol. 2008;44:
430-438.
3. Weber C, Dommerich S, Pau HW, Kramp B. Limited mouth opening after
primary therapy of head and neck cancer. Oral Maxillofac Surg. 2010;14:
169-173.
4. Louise Kent M, Brennan MT, Noll JL, et al. Radiation-induced trismus in
head and neck cancer patients. Support Care Cancer. 2008;16:305-309.
5. Van Cann EM, Dom M, Koole R, Merkx MA, Stoelinga PJ. Health related
quality of life after mandibular resection for oral and oropharyngeal squa-
mous cell carcinoma. Oral Oncol. 2005;41:687-693.
6. Melchers LJ, Van Weert E, Beurskens CHG, et al. Exercise adherence in
patients with trismus due to head and neck oncology: a qualitative study into
the use of the Therabite®. Int J Oral Maxillofac Surg. 2009;38:947-954.
7. Bensadoun RJ, Riesenbeck D, Lockhart PB, et al. A systematic review of
trismus induced by cancer therapies in head and neck cancer patients. Sup-
port Care Cancer. 2010;18:1033-1038.
8. Chen YY, Zhao C, Wang J, et al. Intensity-modulated radiation therapy
reduces radiation-induced trismus in patients with nasopharyngeal carci-
noma: a prospective study with >5 years of follow-up. Cancer. 2011;117:
2910-2916.
9. Scott B, D'Souza J, Perinparajah N, Lowe D, Rogers SN. Longitudinal eval-
uation of restricted mouth opening (trismus) in patients following primary
surgery for oral and oropharyngeal squamous cell carcinoma. Br J Oral
Maxillofac Surg. 2011;49:106-111.
10. Kamstra JI, Dijkstra PU, van Leeuwen M, Roodenburg JL, Langendijk JA.
Mouth opening in patients irradiated for head and neck cancer: a prospective
repeated measures study. Oral Oncol. 2015;51:548-555.
11. Lindblom U, Garskog O, Kjellen E, et al. Radiation-induced trismus in the
ARTSCAN head and neck trial. Acta Oncol. 2014;53:620-627.
12. Steiner F, Evans J, Marsh R, et al. Mouth opening and trismus in patients
undergoing curative treatment for head and neck cancer. Int J Oral Maxillo-
fac Surg. 2015;44:292-296.
13. Wetzels JW, Merkx MA, de Haan AF, Koole R, Speksnijder CM. Maximum
mouth opening and trismus in 143 patients treated for oral cancer: a 1-year
prospective study. Head Neck. 2014;36:1754-1762.
14. van der Geer SJ, Kamstra JI, Roodenburg JL, et al. Predictors for trismus in
patients receiving radiotherapy. Acta Oncol. 2016;55:1318-1323.
15. van den Broek LJ, van der Veer WM, de Jong EH, Gibbs S, Niessen FB.
Suppressed inflammatory gene expression during human hypertrophic
scar compared to normotrophic scar formation. Exp Dermatol. 2015;24:
623-629.
16. Haubner F, Ohmann E, Pohl F, Strutz J, Gassner HG. Wound healing after
radiation therapy: review of the literature. Radiat Oncol. 2012;7:162.
17. King SN, Dunlap NE, Tennant PA, Pitts T. Pathophysiology of radiation-
induced dysphagia in head and neck cancer. Dysphagia. 2016;31:339-351.
18. Amundsen L. Effects of age on joints and ligaments. Kauffman T,
ed. Geriatric rehabilitation manual. New York, NY, Churchill Livingstone,
1999:14-16.
19. Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of
frailty in older cancer patients: a systematic review. Ann Oncol. 2015;26:
1091-1101.
20. Makary MA, Segev DL, Pronovost PJ, et al. Frailty as a predictor of surgical
outcomes in older patients. J Am Coll Surg. 2010;210:901-908.
21. Johnson J, van As-Brooks CJ, Fagerberg-Mohlin B, Finizia C. Trismus in
head and neck cancer patients in Sweden: incidence and risk factors. Med
Sci Monit. 2010;16:CR278-CR282.
22. Teguh DN, Levendag PC, Voet P, et al. Trismus in patients with oropharyn-
geal cancer: relationship with dose in structures of mastication apparatus.
Head Neck. 2008;30:622-630.
70 VAN DER GEER ET AL.
23. Goldstein M, Maxymiw WG, Cummings BJ, Wood RE. The effects of anti-
tumor irradiation on mandibular opening and mobility: a prospective study
of 58 patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;
88:365-373.
24. Beekhuis GJ, Harringtong EB. Trismus. Etiology and management of inabil-
ity to open the mouth. Laryngoscope. 1965;75:1234-1258.
25. Jager-Wittenaar H, Dijkstra PU, Vissink A, van Oort RP, van der Laan BF,
Roodenburg JL. Malnutrition in patients treated for oral or oropharyngeal
cancer–prevalence and relationship with oral symptoms: an explorative
study. Support Care Cancer. 2011;19:1675-1683.
26. Stubblefield MD, Manfield L, Riedel ER. A preliminary report on the effi-
cacy of a dynamic jaw opening device (dynasplint trismus system) as part of
the multimodal treatment of trismus in patients with head and neck cancer.
Arch Phys Med Rehabil. 2010;91:1278-1282.
27. Kamstra JI, Roodenburg JL, Beurskens CH, Reintsema H, Dijkstra PU.
TheraBite exercises to treat trismus secondary to head and neck cancer. Sup-
port Care Cancer. 2013;21:951-957.
28. Pauli N, Fagerberg-Mohlin B, Andrell P, Finizia C. Exercise intervention for the
treatment of trismus in head and neck cancer. Acta Oncol. 2014;53:502-509.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in
the supporting information tab for this article.
How to cite this article: van der Geer SJ, van
Rijn PV, Kamstra JI, et al. Prevalence and prediction
of trismus in patients with head and neck cancer: A
cross-sectional study. Head & Neck. 2019;41:64–71.
https://doi.org/10.1002/hed.25369
VAN DER GEER ET AL. 71
